The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | An update on REVIVE: rusfertide in patients with polycythemia vera
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, explains the mechanism of action of rusfertide and summarizes the results of the Phase II REVIVE trial (NCT04057040). The REVIVE trial included patients with polycythemia vera (PV) requiring phlebotomies with or without cytoreductive therapy. The trial reported that patients treated with rusfertide no longer needed phlebotomies and achieved good hematocrit and ferritin control. In addition, patients reported an improvement in total symptom scores. A Phase III trial (VERIFY – N CT05210790) is currently underway. This interview took place virtually.
